A Phase I, Open-label Study in Patients With Parkinson's Disease to Further Assess Safety and Tolerability of sNN0031 Administered at the Total Dose of 95 microg by Intracerebroventricular Infusion
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2016
At a glance
- Drugs SNN 0031 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Newron Sweden AB
- 26 Jan 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jul 2014 Planned End Date changed from 1 Oct 2014 to 1 Aug 2016 as reported by ClinicalTrials.gov.